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Background  
International Lymphoedema Framework (ILF) and National Frameworks (NLF) 
Chronic oedema remains a worldwide issue. The LIMPRINT© study is at the core of 
the guiding principles of the International Lymphoedema Framework (ILF)(1) The ILF 
is a UK-based charity whose aim is to improve the management of chronic oedema 
and related disorders world-wide through research and the sharing of expertise and 
resources. The ILF comprises of member countries that subscribe to the ideals of the 
ILF and have developed their own independent National Lymphoedema Framework 
(NLF) – a partnership of stakeholders (including: clinicians; academics, patients; 
lymphology organisations and other relevant groups) dedicated to improving chronic 
oedema care. An important part of the ILF strategy is to support countries in 
acquiring and presenting data that will: 
 Establish the size of the problem of chronic oedema  
 Provide the basis for evidence-based practice 
 Be used to facilitate improved reimbursement  
 
Rationale  
The requirements for an international epidemiology study have been previously 
discussed (pages X to X).  This paper describes the methods adopted in the 
development and validation of the LIMPRINT study. 
 
 
LIMPRINT  
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The acronym LIMPRINT stands for Lymphoedema IMpact and PRevalence- 
INTernational and presents the aim of the study; which is “To determine the impact 
and prevalence of chronic oedema within health services at a national and 
international level using a common methodology”. 
LIMPRINT Project overview   
LIMPRINT© was a two-phased project. Phase 1 was conducted between June 2013 
and June 2014 with the development and validation of the methods within two large 
pilot projects. Phase II involved roll out across all sites (9 countries and 26 sites) from 
June 2014 until January 2017.  Table 1 indicates the stages of the project plan 
  
Table 1.  Project plan  
Phase 1 : Development and Validation  
STAGES  
1. Agreement of the research methodologies that could be developed for 
international use in complex health care systems  
2. Literature review of prevalence study methods  and epidemiology 
3. Development of  questionnaires for the core and specialist tools 
4. Development and validation of a classification for chronic oedema  
5. Inter-rater reliability studies (pitting test and classification of chronic oedema 
in different populations ) 
6. Construction and testing of the on-line database 
7. Development of an international protocol and sampling frameworks 
8. Development of a support manual and educational tools 
9. Establishment of quality control mechanisms  
Phase 2 : Main study  
STAGES 
1. Epidemiology studies undertaken in all participating sites 
2. Data quality monitoring 
3. Data analysis and reporting 
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Detailed Project Development  
The stages of the LIMPRINT study are described below. While presented as 
sequential stages many of them ran concurrently over the development phase.  
Phase 1. Stage 1. Agreement of the research methodologies  
The approach taken for the LIMPRINT study was decided during an international ILF 
conference in Montpellier in 2012 (2). Key stakeholders from frameworks and 
methodologists discussed the strengths and limitations of different epidemiological 
approaches within complex and varied health care systems. While it was 
acknowledged that large population based studies were the gold standard this was 
not a realistic option for the following reasons: 
 Lack of  
o international resources  
o census or reliable general population data from which to draw 
random samples.  
o Insurance data for random sampling in public health care systems    
 Large populations would require screening to generate a modest sample size  
 International coding systems do not exist to interrogate existing data sets 
 Bias in population and health service data sets 
The core working group defined the key priority as “The need to uncover the hidden 
burden of chronic oedema on health services”. A method of case ascertainment 
previously used in the UK was adopted as the most flexible approach using the 
following public health definition of chronic oedema (3)(4): 
  
“Chronic oedema is a broad term used to describe oedema which has been 
present for more than three months and involves one or more of the following 
areas: limbs, hands/feet, upper body (breast/chest wall, shoulder, back), 
lower body (buttocks, abdomen), genital (scrotum, penis, vulva), head, neck 
or face.” (3) 
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Primary aim and secondary objectives  
The primary aim of LIMPRINT was “To determine the number of people within health 
services suffering from chronic oedema” Many of these people would not have been 
previously identified or be receiving treatment prior to screening during the study.  
Secondary objectives were defined in order to fulfil the scope of the project and 
were used to determine the study methods and the modular data collection tools. 
(Table 2).   
 
Table 2 – Primary and Secondary Aims of LIMPRINT  
Primary Aim 
To determine the prevalence and functional impact of chronic oedema in the adult 
population within health services at a national and international level using modular 
epidemiological tools. 
Secondary objectives  
 To identify, using a case ascertainment questionnaire (CORE TOOL), all 
patients within defined health services within participating countries, who 
currently suffer from chronic oedema of longer than three months duration. 
 To determine the impact of chronic oedema on the lives of patients using 
questionnaires as follows: 
o Demographic and disability assessment 
o Health related quality of life 
o Details of swelling 
o Wound assessment 
o Cancer assessment 
 To estimate the proportion of patients with chronic oedema who also have a 
wound in the same anatomical area  
 
 
 The project aimed to facilitate the following types of studies within each country: 
 Facility based prevalence studies:  e.g. a general hospital or nursing home   
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 Geographically based prevalence : patients identified in all health services 
contacted in a defined area  
 Specific patient populations:  e.g. specialist Lymphoedema services,  wound 
care clinics  
 In depth evaluation from a random sample  (within facility and geographically 
based studies) 
 
Study infrastructure support and patient involvement  
An international steering group of relevant experts including lymphologists, 
epidemiologists and statisticians met quarterly throughout the project to ensure 
project delivery. A separate data monitoring committee was available to answer any 
questions relating to data issues. 
 
Individual patients and patient organisations within the national frameworks were 
involved in all aspects of the study which conformed to current guidance for patient 
and carer participation (INVOLVE guidelines.)(5)  
 
All countries and sites used the international study protocol and conducted the 
research in accordance with their current ethical and research governance 
regulatory frameworks and the International Declaration of Helsinki(6). All sites 
complied with standard operating procedures on conducting the study and quality 
control mechanisms. 
 Patient inclusion and exclusion criteria  
The study patient inclusion and exclusion criteria are defined in Table 3. 
 
Table 3. Inclusion and Exclusion Criteria  
 Participant/Patient Inclusion criteria 
 The patient is over the age of 18 years. 
 has swelling of longer than 3 months. 
 is able to understand the study as set out in the information sheet. 
 is able to give informed consent, that is, gives explicit consent for their data 
to be transferred into an international data base  
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 Participant/Patient Exclusion criteria 
 is unwilling or unable to participate for whatever reason. 
 is receiving end of life care. 
 When It is considered not to be in the patient’s best interest (decided by the 
lead clinician managing their care). 
 
 
Methods 
In order to comply with the overall study design the presence and chronicity of 
oedema was confirmed by two methods before chronic oedema was judged to be 
present.  This screening test was undertaken at each participating site by staff 
trained in the data collection methods. In specialist Lymphoedema services all 
patients had been assessed by lymphologists prior to data collection and the 
classification of the chronic oedema defined.  
 
Confirmation of chronic oedema was based on the following two factors:  
 First, the existence of oedema was determined on the basis of an 
observational ‘Pitting Oedema Test’, which is widely used in clinical practice 
and been shown to be valid and reliable (7).  The ‘pitting’ test was carried out 
by pressing the thumb into the site of the swelling for 10 seconds.  If a ‘pit’ 
remained upon removal of pressure then ‘pitting oedema’ was judged to be 
present.  Presence of oedema was tested in all body parts, using a standard 
protocol, including the upper and lower limbs, trunk, face and neck. 
 Second, oedema was judged to be chronic if it had been present for three 
months or more.  This factor was determined on the basis of feedback 
received from the patient, or if this was not possible, from carers and 
clinicians who have known the person for at least three months. 
 
Phase 1. Stage 2. Literature review of prevalence study methods  
A literature review of the epidemiological methods had been undertaken under the 
leadership of the American Lymphoedema Framework Project (ALFP) (8). This 
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confirmed the lack of evidence available and informed the design of the study and 
the methods used for data collection.  
 
Phase 1. Stage 3. Development of the core and module data collection methods  
The study design included a core tool which was completed on all patients 
irrespective of the type of study. Additional tools were developed for use in more 
complex projects. The outline of the tools, the methods of use and the data they 
provide are outlined in Table 4.  
 
 
Table 4. Tools, methods and data delivered  
 
Tool Method Deliverables 
Core Tool 
 
Core case ascertainment 
questionnaire.  
 
Identification of patients 
with chronic oedema in 
health care systems 
 
Used in all studies  
 
 
 
Questionnaire completed 
by healthcare professionals  
 
Chronic  oedema confirmed 
by pitting test and 
confirmation of history of 
chronic oedema > 3months  
 
 
 Prevalence of patients 
with chronic oedema 
 
 Age/gender/duration and 
site of swelling 
 
 Subjective control of 
swelling 
 
 Level of obesity 
 
 Mobility 
 
 Relevant co-morbidities 
 
 Classification of cause of 
chronic oedema 
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 Previous treatment 
 
 Cellulitis history 
 
 Presence of a wound 
 
 Access to treatment 
 
Module Tools 
 
Assessment of functional 
impact. 
 
 Demographics & 
Disability 
assessment 
(WHODAS 2.0) 
 
 Quality of life 
assessment 
(LYMQOL + EQ-5D+ 
LFSQQ) 
 
 Details of swelling 
 
 Wound 
assessment 
 
 Cancer details 
 
 
 
Data was gathered from 
patients using clinical 
assessment and interviews, 
either by self-completion or 
completion by a health 
professional.  
 
 
 
 
The Module Tools collected data 
that looked in more depth at 
factors affecting the life of the 
patient as well as care delivery 
such as the impact on discharge 
from hospital or accessing 
appropriate care including: 
 
 Personal details including 
living status, educational 
attainment, employment 
status 
 
 Details of swelling 
 
 Mobility status 
 
 Quality of life 
 
 Impact of cancer 
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 Type and impact of wound 
 
 Factors affecting delivery 
of care and discharge 
 
 Resource use 
 
 
 
Development of the Core Tool  
The development of the Core Tool followed a consultative approach with an 
International expert panel and eight participating NLF frameworks. The resulting 
Core Tool had 13 domains (Table 5).  The initial questions were generated within an 
international conference (4th International Lymphoedema Framework Conference, 
June 2012, Montpellier, France) and the questions ranked in order of importance. 
The tool initially included 21 domains but this was reduced to 13 following the 
consultation process.  
 
The questions covered the most vital information required to understand the 
prevalence of chronic oedema and its impact on health services. The tool was simple 
and rapid to complete. Translation and back translation of the core, wound and 
swelling tools have been undertaken in Danish, French and Japanese thus adding 
another level of validation. 
 
Data fields within the Core Tool 
 
The Core tool identified key information about access to care and the types of 
treatment. This included whether any treatment was being given currently or not. 
For those receiving treatment, data was collected on the elements of complex 
decongestive therapy: skin care; exercise; manual lymphatic drainage and types of 
compression. Other treatments noted included antibiotics, psychological support 
and surgical treatments and liposuction.  
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A body map was used to record the sites of swelling and the presence and nature of 
any concurrent wounds. Lower and upper mobility status was defined using a 
previously published classification (9). Information about the history of cellulitis and 
treatment was recorded including use of antibiotics and episodes requiring 
hospitalisation. A WHO general category of weight was adopted due to the lack of 
available BMI for many, particularly those seen in community settings. (10). Important 
co-morbidities linked to chronic oedema were also recorded. 
 
The teams screening the patient were asked to make a subjective judgement about 
whether the swelling was controlled or not. Whilst it is recognised that this 
questions is open to professional interpretation, nevertheless this is an important 
question that has previously been linked to whether patients are accessing 
treatment (3). As the data was collected by pairs or teams of researchers such a 
judgement could be clarified if there were issues of discrepancy.  
 
Further questions examined whether chronic oedema was a factor in determining or 
delaying discharge from hospital or were a reason for long term community care.  
Issues of access to specialist treatment and the distance from services were also 
recorded. 
  
Table 5. The domains of the Core Tool 
 
1. Type of facility in which data is 
collected 
2. Demographics 
3. Level of obesity 4. Mobility 
5. Relevant co-morbidities 6. Classification of lymphoedema 
7. Lymphoedema history 8. Cellulitis History 
9. Categories of treatment 10. Site of swelling 
11. Wound area 12. Access to treatment 
13. Subjective control of swelling  
 
      
11 
 
Expert review of the Core tool 
Each of the 8 participating frameworks engaged 10 professionals (generalists and 
specialists) to review the core tool using a set of 5 validated case studies to complete 
the tool and decide the classification. The data was entered into the database and 
the results were compared by 5 independent lymphologists for accuracy of 
classification and data quality. Of the 400 complete case reviews correct 
classification occurred in 387 /400 (97%).  The 13 cases in which classification 
differed related to the decision about whether the case was due to primary or 
secondary lymphoedema. This is a well-known and valid difficulty for clinicians. 
 
Module Tools  
The Module Tools aimed to assess the functional and quality of life impact using 
validated tools where possible. Further clinical information about wounds and 
treatment, where present, and details of the severity of swelling were included.  
Module Tools covered the following areas: 
 
Demographics and disability (WHODAS 2.0) 
This well validated tool included questions that explored the patient’s personal 
circumstances e.g. housing, employment and education. WHODAS 2.0 is a 12-item 
disability assessment schedule completed by the patient (11). 
 
Quality of Life (LYMQOL & EQ-5D & LFSQQ) 
Quality of life was assessed with a combination of disease specific and generic tools.  
 LYMQOL is a validated condition-specific quality of life assessment 
instrument (it is not validated for patients with lymphatic filariasis) that 
assesses the impact of lymphoedema on the patient’s everyday living and 
health related quality of life. The tool is validated for lower and upper body. 
(12) 
 EQ-5D is a generic quality of life instrument applicable to a wide range of 
health conditions and provides a simple descriptive profile and single index 
value for health status. (13). 
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 LFSQQ (Lymphatic Filariasis Specific Quality of Life Questionnaire) is a 
condition-specific instrument for patients with lymphatic filariasis. The LFSQQ 
is intended for use for patients within filarial areas and the questionnaire was 
developed based on an Indian lifestyle. (14).   
 
Details of swelling 
This tool provided further details about the swelling. Each study site elected one 
measurement technique which was standardised for all patients.  
 
Limb circumference and volume measures 
Standardised circumferential limb measurements using a tape measure were the 
most widely used and accessible technique.  Upper and lower limb circumference 
were measured bilaterally at two points according to the site of swelling: 
o mid-upper arm (10cm proximal to the olecranon process) 
o forearm (10cm distal to the olecranon process) 
o mid-thigh (20cm proximal to the patella) 
o calf (20cm distal to the patella) 
 
Limb volume methods (specialist centres) 
Limb volume measures were undertaken in specialist centres with access to this 
expertise. Limb volume was expressed in millilitres for each limb using a standard 
method for all patients within the study site. The methods included water 
displacement and perometry 
 
Kaposi-Stemmer sign 
The Kaposi-Stemmer sign involved pinching a skin fold at the base of the second toe 
or middle finger of the limb that had oedema (15).  The sign was judged to be positive 
if the skin could not be lifted and negative if the skin could be lifted normally. 
Collectively, these data were used to describe and classify severity using the 
International Society of Lymphology staging tool (16)(17)(18) 
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 ISL stage I: Early onset of the condition where there is accumulation of tissue 
oedema that subsides with limb elevation.  The oedema may be pitting at this 
stage. 
 ISL stage II: Limb elevation alone rarely reduces swelling and pitting is 
manifest.   
 ISL stage III: The tissue is hard (fibrotic) and pitting is absent.  Skin changes 
such as thickening, hyper-pigmentation, increased skin folds, fat deposits and 
warty overgrowths develop. 
 
Wounds 
This tool provided data about all wounds including: type of wound, location, 
severity, wound area, wound duration, history of infection and frequency of dressing 
changes. 
 Cancer 
A specific tool for patients whose chronic oedema was the consequence of cancer 
treatment or a direct effect of the disease was developed. This was a fourteen-
domain questionnaire focusing on types of cancer and surgical and non-surgical 
treatments. The types of cancer included were: 
 
Breast  Cervical cancer 
Endometrial  Ovarian  
Bladder  Vulval  
Colorectal  Melanoma  
Head and Neck  Other cancers 
 
 
 
 
Phase 1. Stage 4. Development and validation of a classification for chronic 
oedema  
A fifteen member expert panel reviewed and assessed a set of eight case studies for 
content and face validity and to ensure that they reflected the chronic oedema 
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classification categories contained in the Core Tool. There was a 100% response rate. 
Five of the eight case studies achieved a 90% agreement level for the classification of 
lymphoedema and these five case studies were used for the review of the core tool 
in stage 4. 
 
The classification required a decision was made on whether the chronic oedema was 
of primary origin or due to a secondary causes (Table 6.)  In those with a secondary 
cause a number of key suspected risk factors were included including venous disease 
and obesity. During the studies specialist lymphology teams undertook this 
classification where patients had been identified and confirmed to have chronic 
oedema.   
Table 6 
Classification of chronic oedema:  
 
Primary Lymphoedema  
Secondary Lymphoedema  Cancer  
 Non Cancer  
 Risk factors: Venous disease, obesity, 
immobility, other (free text)   
 
 
 
 
 
 
Stage 5. Inter-rater reliability studies  
 
The LIMPRINT study included a number of inter-rater reliability studies to assess the 
accuracy of detection of chronic oedema using the pitting test and the other 
methods of clarification. 
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Dai et al (7) undertook a cross sectional study within a long term care hospital in 
Japan. The inter-rater reliability of the pitting test for evaluating oedema was tested 
for 34 locations of the body. The pitting test was applied for 10 seconds with a 
similar force to that used by the expert assessor who acted as a “gold standard”.  
Detection of the presence of oedema on removal of pressure was assessed using the 
modified Fukazawa method (19) described in Table 7. 
 
 
Table 7. Modified Fukazawa method of assessment for detection of pitting oedema  
Grade  Criteria 
0 There is no impression (no oedema present)  
1 Impression of the outline of the dimple is slightly differentiated by release of 
pressure and sometimes appears to be absent 
2 Impression does not become clear at the beginning of pressure but occurs with 
further pressure and an impression is left after release 
3 Deep impression remains after release of pressure that is clear on visual 
inspection at initiation of pressure  
Non Pitting 
Oedema  
(added to 
method ) 
Indentation made by pressure does not persist (non - pitting oedema as seen in 
patients with chronic skin changes with fibrosis  ) 
 
Five bedridden patients were assessed by the gold reference and four independent 
assessors. Agreement among the assessors was high at > 0.85 with the kappa 
coefficient showing fair agreement (range 0.51- 0.81) (Table 8) 
 
Table 8.  Inter-rater reliability results from Japan 
Rater ID Agreement rate with “gold standard” Cohen’s kappa coefficient  
1 0.88 0.51 
2 0.90 0.60 
3 0.94 0.81 
4 0.88 0.51 
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The same methodology was used in three UK studies. Two of the studies involved 
patients seen by community nursing services and one with patients within a 
residential care facility. Results from these studies confirmed a high rate of detection 
of chronic oedema although mild oedema was missed by a proportion of community 
nurses compared to the expert assessor.  
 
Phase 1. Stage 6.  Construction and testing of the on-line database 
 
Security and international requirements of the online data base  
LIMPRINT data was managed by an electronic data management system that had a 
comprehensive set of security features that included the storage of data in 
encrypted form and individualised password controlled access. The system had an 
audit trail, which tracked all activity on the system including changes to data. As an 
added security feature the user was automatically logged out after 10 minutes of 
inactivity, requiring a password to restart the application. An edit check function in 
the form of a Data Clarification Form was developed in order to check for flagging, 
missing, invalid, incomplete or questionable data and required study site clarification 
before the data was marked as complete. Individual sites had access to only their 
own data. The project manager and statisticians  were able to access all data from 
the sites.    
 
During the project the data system was evaluated by the participating frameworks to 
ensure that it was fit for purpose and to access the training requirements for each 
site. Central training for all users was undertaken by ILF project manager and data 
management team.  
 
Data transfer and compliance  
The study faced a number of important considerations relating to data protection 
and transfer of data. For countries within the European Union, the EU Data 
Protection Directive guides such legislation and there are restrictions on the 
exporting of confidential data to countries outside the EU. This includes the United 
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States where the database was located. Within these restrictions the transfer of data 
was permitted as long as three criteria were met: 
 There was confirmation that the system complied with all EU Data Protection 
legislations and could ensure that sensitive health data was protected. 
 The data was anonymised.  
 Patients gave explicit consent to the transfer of their data to a country 
outside the EU. 
In sites where transfer of data outside of Europe was prohibited due to research 
governance issues the data was entered on to a password protected data collection 
system using the same data capture fields. 
 
Phase 1. Stage 7. Development of an international protocol and sampling 
frameworks 
The international protocol included a detailed description of the sampling 
procedures and study methods and was used in all sites. 
 
Methods for sampling in geographically based prevalence study 
A comprehensive list was collated for each geographical area of all acute hospitals 
and relevant community health services that may come into contact with people 
who have chronic oedema.  Examples of such services included:   
 
o General medical practitioner.  
o Specialist community medical practitioner. 
o Community nursing/home care nursing service. 
o Nursing home. 
o Elderly care residential home. 
o Specialist lymphoedema service. 
o Acute hospital services (in-patient or/and outpatient) 
 
A sampling frame was created with the recruitment strategy aimed to ensure the 
widest range of patients were identified with different underlying conditions and co-
morbidities.  
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Hospital cased prevalence studies  
In hospital settings, a sampling framework of all wards and departments in which 
patients with chronic oedema would be found was developed. The screening was 
undertaken in a single day or over a number of days in larger facilities.  Trained staff 
screened all patients who consented to participate irrespective of their underlying 
disease or treatment regimen. Teams of researchers undertook the study with a 
lymphologist assigned to each team in order to undertake the chronic oedema 
classification. 
 
The bed capacity of each ward or unit was recorded, plus the number of beds 
occupied, the number of patients recruited and the number excluded from 
consideration and the reasons for this. This enabled the prevalence to be calculated 
accurately in hospital settings.   
 
Community based prevalence studies  
All staff in relevant community health services were asked to approach each person 
on their existing case list to provide information and gain consent. All generalist 
practitioners participating in the study received training in the completion of the 
tools. The collection of data took place prospectively over a time frame, generally of 
two weeks and required all patients to be clinically screened and assessed. Numbers 
on community caseloads were recorded and those excluded from the study. The 
method of classification of chronic oedema varied in different settings but included 
the use of specialist lymphoedema therapist and tissue viability teams in some 
settings. In areas where this support was not available the more detailed 
classification was omitted (3 studies in the UK).  
 
Random sample 
A random sample was used in some population or facility based studies, where large 
numbers of patients with chronic oedema were identified but additional modular 
tools were required. A random permuted block design allowed for a one third 
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sample to be taken.  Following completion of the Core tool the investigator checked 
the patient numbers of those identified with chronic oedema against a pre-
generated randomised list of sequential patient numbers to decide whether the 
patient was to be interviewed. Each clinical team held an individual randomisation 
list.  
 
 
Specialist service profiles  
LIMPRINT provided a unique opportunity to understand the profile of patients seen 
within specialist Lymphoedema and other types of services in different countries and 
to compare this with patients found in other settings. Patients gave informed 
consent for their inclusion and the accuracy of the service lists were checked to 
ensure that it was up to date and discharge and deaths had been removed. 
Information on their oedema status was based on their last visit and the type of 
lymphoedema was taken from the clinical case records.  
 
Phase 1. Stage 8. Development of a support manual and educational tools 
LIMPRINT required the development of a range of educational materials to ensure 
that the data was collected accurately. This included a manual to supplement the 
protocol. Formal training standards were written that included a checklist of training 
and competency for all those collecting data.  A video using re-useable learning 
outcomes was made to demonstrate how to undertake the pitting test, recognition 
of a positive stemmer sign and fibrosis. All facility based studies commenced with a 
half day training programme that included checking of the first assessment by 
specialist practitioners. Data quality was enhanced by teams of researchers working 
in clinical areas where any complex clinical questions could be confirmed before 
leaving the area. 
 
Phase 1. Stage 9. Establishment of quality control mechanisms 
 
A number of quality control mechanisms were established. 
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Preventing double counting 
The prevention of double counting was essential in order to achieve an accurate 
prevalence. The double counting of patients was likely to take place within a 
geographical area when a patient might be identified by more than one service 
delivering care to the same patient or in an acute care setting if a patient moved 
departments. This was prevented by the allocation of a non-identifiable number that 
was matched with a master identifier list of patients. 
 
Data quality checks  
In addition to the quality checks within the electronic data system additional checks 
were made of the paper based data collection tools. Within each facility quality 
monitors were established to check completeness of data from each clinical area 
before the research teams left the area and all forms were checked by a central co-
ordinator. Similar mechanisms were established for community studies.                                                                                                                                               
 
 Conclusion 
 
The standardisation of methods used in The LIMPRINT study provided a framework 
that allowed sites in different countries and from different facilities and types of 
health care systems to work together and demonstrated the ability for an 
international initiative to be undertaken that  was supported by a strong ethos of 
partnership. The results from the different studies will be presented in the following 
papers 
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